Original Research

DOI: 10.4244/EIJ-D-24-00662

Long-term structural valve deterioration after TAVI: insights from the EORP ESC Valve Durability TAVI Registry

Cristina Giannini1, MD, PhD; Davide Capodanno2, MD, PhD; Gabor G. Toth3, MD, PhD; Stephan Windecker4, MD; Stefanie Schüpke5, MD; Daniel J. Blackman6, MD; Stéphane Noble7, MD; Hélène Eltchaninoff8, MD; Claudia Fiorina9, MD; Alaide Chieffo10, MD; Antonio L. Bartorelli11, MD; Albrecht Schmidt12, MD; Ole De Backer13, MD; Martine Gilard14, MD, PhD; Elizabeth Curtis15, MD; Guillaume L’Official15, MD, PhD; Erwan Donal15, MD, PhD; Cécile Laroche16; Bernard Prendergast17,18, MD; Anna Sonia Petronio1, MD; on behalf the European Valve Durability TAVI Registry investigators

Abstract

Background: Valve durability is a key consideration as the patient population eligible for transcatheter aortic valve implantation (TAVI) expands to include lower-risk and younger individuals who are expected to live many years after the procedure.

Aims: This registry aimed to assess the incidence of long-term structural valve deterioration (SVD) beyond 5 years post-TAVI.

Methods: Consecutive living patients who underwent TAVI up until 2014 using any commercially available transcatheter heart valve (THV) at 22 participant centres were enrolled in the European Valve Durability TAVI Registry. All patients underwent comprehensive echocardiographic assessments (61% were evaluated independently by a central core laboratory) within 6 months of enrolment and at least 5 years post-TAVI; SVD was defined according to Valve Academic Research Consortium 3 definitions.

Results: A total of 597 patients (aged 79.6±7.1 years at the time of TAVI; 47.2% male, mean Society of Thoracic Surgeons score 5.0%) were included. At a median of 6.1 years of follow-up (interquartile range 5.2-7.3 years), the crude incidence of moderate/severe SVD was 9.5% (n=57; moderate: 6.2%, n=37; severe: 3.4%, n=20). Predictors of SVD identified by Cox regression analysis were use of an intra-annular THV (hazard ratio [HR] 38.44, 95% confidence interval [CI]: 10.8-136.3; p<0.001), a small THV size (HR 4.82, 95% CI: 2.42-9.60; p<0.001) and moderate/severe postprocedural paravalvular leak (HR 3.64, 95% CI: 1.59-8.32; p=0.002).

Conclusions: The incidence of moderate/severe SVD during long-term follow-up after TAVI is low, with severe SVD being even rarer than moderate SVD. SVD occurs more frequently in patients treated with older-generation intra-annular valves and in those with small-sized THVs.

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 21 Number 10
May 16, 2025
Volume 21 Number 10
View full issue


Key metrics

Suggested by Cory

10.4244/EIJV15I10A160 Nov 15, 2019
Durability of transcatheter bioprosthetic aortic valves: the story so far
Capodanno D et al
free

10.4244/EIJV14I15A263 Feb 7, 2019
Valve durability – is this the Achilles’ heel of TAVI?
Jabbour R and Mikhail G
free

10.4244/EIJV11SWA34 Sep 17, 2015
Durability of devices: long-term results and clinical outcomes
Arsalan M and Mack MJ
free

10.4244/EIJV14I4A67 Jul 20, 2018
TAVI durability beyond five years: no alarms, but stay alert
Eltchaninoff H et al
free

Editorial

10.4244/EIJ-E-25-00024 Jul 7, 2025
The new balloon-expandable Myval transcatheter heart valve: only good news?
Pibarot P and Van Belle E
free

AORTIC VALVE INTERVENTIONS

10.4244/EIJV12SYA8 Sep 18, 2016
Late degeneration of transcatheter aortic valves: pathogenesis and management
Barbanti M and Tamburino C
free
Trending articles
225.25

State-of-the-Art Review

10.4244/EIJ-D-21-00426 Dec 3, 2021
Myocardial infarction with non-obstructive coronary artery disease
Lindahl B et al
free
172.05

Focus article

10.4244/EIJY19M08_01 Jan 17, 2020
EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update
Glikson M et al
free
80.3

State-of-the-Art

10.4244/EIJ-D-24-00066 Apr 21, 2025
Management of complications after valvular interventions
Bansal A et al
free
47

Original Research

10.4244/EIJ-D-25-00331 May 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved